Alexion Pharmaceuticals (ALXN) PT Lowered to $161 as Raymond James Sees Pegcetacoplan Gaining the Lead
Tweet Send to a Friend
Raymond James analyst Steven Seedhouse lowered the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $161.00 (from $170.00) acknowledging the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
